ReviewFrontiers in aging neuroscience2014
The intriguing regulators of muscle mass in sarcopenia and muscular dystrophy.
Review in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- In-vitro human myogenesis model reveals novel mRNA alternative splicing isoforms.Scientific reports · 2025Article
- Deciphering the role of IGFBP5 in delaying fibrosis and sarcopenia in aging skeletal muscle: therapeutic implications and molecular mechanisms.Frontiers in pharmacology · 2025Article
- "Monitoring inflammatory, immune system mediators, and mitochondrial changes related to brain metabolism during space flight".Frontiers in immunology · 2024Review
- Possible-sarcopenic screening with disturbed plasma amino acid profile in the elderly.BMC geriatrics · 2023Article
- Effects of changes in skeletal muscle mass on the prognosis of pediatric malignant solid tumors.Pediatric surgery international · 2022Article
- Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms and their haplotypes in susceptibility to sarcopenia in Iranian older adults.BMC geriatrics · 2022Article
- Review
- Aging-related hyperphosphatemia impairs myogenic differentiation and enhances fibrosis in skeletal muscle.Journal of cachexia, sarcopenia and muscle · 2021Article
- Article
- Article
- Metabolomic analysis of primary human skeletal muscle cells during myogenic progression.Scientific reports · 2020Article
- Article
- Altered gene and protein expressions of vitamin D receptor in skeletal muscle in sarcopenic patients who sustained distal radius fractures.Journal of bone and mineral metabolism · 2019Article
- Myostatin dysfunction does not protect from fasting-induced loss of muscle mass in mice.Journal of musculoskeletal & neuronal interactions · 2019Article
- DNA methylation in the pathogenesis of type 2 diabetes in humans.Molecular metabolism · 2018Review
- Chemotherapy dosing and toxicity in a patient with muscular dystrophy.Cancer reports (Hoboken, N.J.) · 2018Article
- Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.PloS one · 2018Article
- Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy.PloS one · 2018Article
- Targeted quantification of lipid mediators in skeletal muscles using restricted access media-based trap-and-elute liquid chromatography-mass spectrometry.Analytica chimica acta · 2017Article
- Urolithin B, a newly identified regulator of skeletal muscle mass.Journal of cachexia, sarcopenia and muscle · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in our understanding of the biology of muscle have led to new interest in the pharmacological treatment of muscle wasting. Loss of muscle mass and increased intramuscular fibrosis occur in both sarcopenia and muscular dystrophy. Several regulators (mammalian target of rapamycin, serum response factor, atrogin-1, myostatin, etc.) seem to modulate protein synthesis and degradation or transcription of muscle-specific genes during both sarcopenia and muscular dystrophy. This review provides an overview of the adaptive changes in several regulators of muscle mass in both sarcopenia and muscular dystrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.